Teva Joins 8 Drugmakers in $19.6B US Deal
Teva Pharmaceuticals and eight other companies have signed a deal with the US government to lower Medicaid drug prices, committing to Most Favoured Nation pricing and investing at least $19.6 billion in US manufacturing
Teva Pharmaceuticals, along with eight other drugmakers, has signed a deal with the US government to lower drug prices for Medicaid programs. The agreement includes a commitment to Most Favoured Nation pricing for US Medicaid and future innovative medicine launches.
The deal is part of President Donald Trump's initiative to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations. The nine drugmakers, including Teva Pharmaceuticals, will collectively invest at least $19.6 billion in US manufacturing in the near term.
The agreement will provide every State Medicaid programme in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans. The deal also includes a commitment to strengthen US pharmaceutical supply chains.
Teva Pharmaceuticals, along with the other eight drugmakers, will avoid tariffs on innovative pharmaceutical products for more than two years. The US is the largest market for Teva Pharmaceuticals' innovative medicines, accounting for approximately 27% of its global revenue.
The agreement was announced on August 31, following a White House signing ceremony attended by the nine pharmaceutical companies. The nine pharmaceutical companies, including Teva Pharmaceuticals, will contribute to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) in the US.
## Why it matters The deal is significant as it will provide affordable medicines to Americans and strengthen the US pharmaceutical supply chain. The agreement is also important for Teva Pharmaceuticals, as the US is its largest market for innovative medicines. The company's commitment to Most Favoured Nation pricing and investment in US manufacturing demonstrates its long-term strategy to expand its presence in the US market.
The agreement comes amid the Trump administration's efforts to lower prescription drug prices and expand its most-favoured-nation pricing push. The deal is expected to have a positive impact on the US healthcare system, providing billions of dollars in savings for Americans and improving access to affordable medicines.
